Celikey tTG | EMA | |||||
Celikey tTG-negative n = 6647 | Celikey tTG-positive n = 202 | p Value | EMA-negative n = 6776 | EMA-positive n = 73 | p Value | |
Cancer, all sites | ||||||
Cases | 671 | 23 | 689 | 5 | ||
Relative risk (95% CI)* | 1.00 | 0.91 (0.60 to 1.37) | 0.64 | 1.00 | 0.67 (0.28 to 1.61) | 0.33 |
Lymphoproliferative disease | ||||||
Cases | 28 | 3 | 29 | 2 | ||
Relative risk (95% CI)* | 1.00 | 2.76 (0.83 to 9.16) | 0.15 | 1.00 | 5.94 (1.41 to 25.04) | 0.05 |
Gastrointestinal cancer | ||||||
Cases | 115 | 6 | 121 | 0 | ||
Relative risk (95% CI)* | 1.00 | 1.38 (0.60 to 3.14) | 0.47 | 1.00 | 0.00 (–) | 0.12 |
Lung cancer | ||||||
Cases | 83 | 2 | 85 | 0 | ||
Relative risk (95% CI)* | 1.00 | 0.73 (0.18 to 2.97) | 0.64 | 1.00 | 0.00 (–) | 0.26 |
Breast cancer, women | ||||||
Cases† | 89 | 2 | 90 | 1 | ||
Relative risk (95% CI)* | 1.00 | 0.64 (0.16 to 2.59) | 0.49 | 1.00 | 0.71 (0.10 to 5.07) | 0.71 |
Prostate cancer, men | ||||||
Cases‡ | 56 | 1 | 57 | 0 | ||
Relative risk (95% CI)* | 1.00 | 0.54 (0.07 to 3.90) | 0.50 | 1.00 | 0.00 (–) | 0.41 |
*Age- and sex-adjusted. †Only women at risk were included. ‡Only men at risk were included.